Similarly, a phase 2 study assessing the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib in patients with recurrent, platinum-resistant ovarian cancer closed at interim analysis due to a low objective response rate of 7% [10]. This evidence concerns the gene PDCD1 and ovarian carcinoma.